临床心身疾病杂志
臨床心身疾病雜誌
림상심신질병잡지
JOURNAL OF CLINICAL PSYCHOSOMATIC DISEASES
2015年
3期
32-34
,共3页
柴艳丽%余学%张慧芳%王丽
柴豔麗%餘學%張慧芳%王麗
시염려%여학%장혜방%왕려
精神分裂症%急性期%激越症状%利培酮%氯硝西泮%氟哌啶醇%阳性与阴性症状量表
精神分裂癥%急性期%激越癥狀%利培酮%氯硝西泮%氟哌啶醇%暘性與陰性癥狀量錶
정신분렬증%급성기%격월증상%리배동%록초서반%불고정순%양성여음성증상량표
Schizophrenia%acute phase%agitated symptom%risperidone%clonazepam%haloperidol%PANSS
目的:探讨利培酮联合氯硝西泮与氟哌啶醇治疗精神分裂症患者急性激越症状的疗效和安全性。方法将69例伴急性激越症状的精神分裂症患者随机分为两组,研究组口服利培酮联合氯硝西泮治疗,对照组予以氟哌啶醇治疗,观察4周。于治疗前后采用阳性与阴性症状量表总分及兴奋因子分评定临床疗效,副反应量表评定不良反应。结果治疗后两组阳性与阴性症状量表总分及兴奋因子评分较治疗前持续下降( P<0.01),治疗4周末研究组显效率57.1%、有效率97.1%,对照组分别为50.0%、100%,两组比较差异均无显著性(χ2=0.35、0.99,P>0.05)。研究组不良反应发生率为37.1%、苯海索使用率为8.6%,对照组分别为64.7%、44.1%,研究组显著低于对照组(χ2=5.24、11.30,P<0.05或0.01)。结论利培酮联合氯硝西泮能够快速有效控制精神分裂症急性激越症状,疗效与氟哌啶醇相当,但安全性更高,具有长程治疗优势,有利于患者的连续性治疗。
目的:探討利培酮聯閤氯硝西泮與氟哌啶醇治療精神分裂癥患者急性激越癥狀的療效和安全性。方法將69例伴急性激越癥狀的精神分裂癥患者隨機分為兩組,研究組口服利培酮聯閤氯硝西泮治療,對照組予以氟哌啶醇治療,觀察4週。于治療前後採用暘性與陰性癥狀量錶總分及興奮因子分評定臨床療效,副反應量錶評定不良反應。結果治療後兩組暘性與陰性癥狀量錶總分及興奮因子評分較治療前持續下降( P<0.01),治療4週末研究組顯效率57.1%、有效率97.1%,對照組分彆為50.0%、100%,兩組比較差異均無顯著性(χ2=0.35、0.99,P>0.05)。研究組不良反應髮生率為37.1%、苯海索使用率為8.6%,對照組分彆為64.7%、44.1%,研究組顯著低于對照組(χ2=5.24、11.30,P<0.05或0.01)。結論利培酮聯閤氯硝西泮能夠快速有效控製精神分裂癥急性激越癥狀,療效與氟哌啶醇相噹,但安全性更高,具有長程治療優勢,有利于患者的連續性治療。
목적:탐토리배동연합록초서반여불고정순치료정신분렬증환자급성격월증상적료효화안전성。방법장69례반급성격월증상적정신분렬증환자수궤분위량조,연구조구복리배동연합록초서반치료,대조조여이불고정순치료,관찰4주。우치료전후채용양성여음성증상량표총분급흥강인자분평정림상료효,부반응량표평정불량반응。결과치료후량조양성여음성증상량표총분급흥강인자평분교치료전지속하강( P<0.01),치료4주말연구조현효솔57.1%、유효솔97.1%,대조조분별위50.0%、100%,량조비교차이균무현저성(χ2=0.35、0.99,P>0.05)。연구조불량반응발생솔위37.1%、분해색사용솔위8.6%,대조조분별위64.7%、44.1%,연구조현저저우대조조(χ2=5.24、11.30,P<0.05혹0.01)。결론리배동연합록초서반능구쾌속유효공제정신분렬증급성격월증상,료효여불고정순상당,단안전성경고,구유장정치료우세,유리우환자적련속성치료。
Objective To explore the efficacy and safety of risperidone combined with clonazepam vs .halo‐peridol in schizophrenia with acute agitated symptoms .Methods Sixty‐nine schizophrenics with acute agi‐tated symptoms were randomly divided into two groups ,research group was treated with risperidone plus clonazepam orally and control group with haloperidol for 4 weeks .Efficacies were assessed with the total and excitation score of the Positive and Negative Syndrome Scale (PANSS) before and after treatment and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results After treatment the to‐tal and excitation scores of the PANSS of both groups lowered continuously compared with pretreatment (P<0 .01) ,at the end of the 4th week obvious effective and effective rate were respectively 57 .1% and 97 .1% in research and 50 .0% and 100% in control group ,which showed no significant differences (χ2 =0 .35 ,0 .99 ;P>0 .05) .The incidence of adverse reactions was 37 .1% and benzhexol use rate 8 .6% in re‐search and 64 .7% and 44 .1% in control group ,the former was significantly lower than the latter (χ2 =5 .24 ,11 .30 ;P<0 .05 or 0 .01) .Conclusion Risperidone combined with clonazepam could rapidly and ef‐fectively control schizophrenic acute agitated symptoms ,has an equivalent effect to haloperidol ,higher safety and a long‐term treatment advantage ,and is beneficial to patients’ continuous treatment .